WAVE Life Sciences (STU:1U5) Change In Receivables : €-0.08 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences Change In Receivables?

WAVE Life Sciences's change in receivables for the quarter that ended in Mar. 2025 was €1.32 Mil. It means WAVE Life Sciences's Accounts Receivable declined by €1.32 Mil from Dec. 2024 to Mar. 2025 .

WAVE Life Sciences's change in receivables for the fiscal year that ended in Dec. 2024 was €18.78 Mil. It means WAVE Life Sciences's Accounts Receivable declined by €18.78 Mil from Dec. 2023 to Dec. 2024 .

WAVE Life Sciences's Accounts Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. WAVE Life Sciences's Days Sales Outstanding for the three months ended in Mar. 2025 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. WAVE Life Sciences's liquidation value for the three months ended in Mar. 2025 was €117.05 Mil.

WAVE Life Sciences Change In Receivables Historical Data

The historical data trend for WAVE Life Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Change In Receivables Chart

WAVE Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

16.44

26.55

-19.34

18.78

WAVE Life Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															19.40	-1.20	1.16	-1.36	1.32

WAVE Life Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08 Mil.

WAVE Life Sciences (STU:1U5) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

WAVE Life Sciences's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	8.487	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, WAVE Life Sciences's accounts receivable are only considered to be worth 75% of book value:

WAVE Life Sciences's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	224.844	-	107.799	+	0.75 * 0	+	0.5 * 0
=	117.05

WAVE Life Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

WVE:USA 1U5:Germany

Address

7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines